The Times Australia
Google AI
Health

.

Ivermectin is still not a miracle cure for COVID-19, despite what you may have read

  • Written by Andrew McLachlan


The head lice drug ivermectin has yet again been touted in the media as a possible treatment for COVID-19. But despite the favourable headlines, huge uncertainty remains about whether this treatment can be safely and effectively repurposed to tackle the coronavirus.

In recent weeks the media has been awash with claims ivermectin, when given in combination with the common antibiotic doxycycline and zinc supplements, is effectively a “cure” for COVID-19.

Yet there has been no definitive clinical trial so far showing this is the case. All we have are observational studies and clinicians’ opinions.

The World Health Organisation’s database of clinical studies for COVID-19 shows there are currently 16 trials investigating ivermectin. Even these studies are unlikely to provide the high-quality data necessary to show ivermectin can actually provide its touted benefits.

Get your news from people who know what they’re talking about.

Many of the current studies have low numbers of participants, weak study designs, and inconsistent (and relatively low) ivermectin dosing regimes, with ivermectin frequently given in combination with other drugs.

The Royal Australian Council of General Practitioners and the Australian Commission for Quality and Safety in Health Care have warned there is insufficient evidence ivermectin is a safe and effective treatment for people infected with the coronavirus.

What do we know about ivermectin for COVID-19?

Laboratory studies using monkey cells in a test tube (as opposed to clinical studies in human patients) have shown ivermectin can shut down the replication of SARS-CoV-2, the coronavirus that causes COVID-19, within 24-48 hours of exposure to the drug.

Ivermectin is thought to inhibit the virus by preventing viral proteins moving in and out of the host cell’s nucleus, which is essential for replication of the coronavirus.


Read more: Head lice drug Ivermectin is being tested as a possible coronavirus treatment, but that's no reason to buy it


The problem is this process requires very high concentrations of ivermectin – well above the recommended dose for humans. This means ivermectin’s virus-killing powers would be unlikely to be harnessed inside the human body.

A detailed analysis of the relationship between dose and concentration of ivermectin suggests none of the currently used ivermectin dosing regimens would deliver high enough concentrations of ivermectin inside the body to activate its virus-killing effects.

Another review backs this up, suggesting all of the ivermectin doses being investigated in current clinical trials would fall well short of achieving drug concentrations high enough to wipe out SARS-CoV-2.

Even a 120 mg dose of ivermectin, which would be regarded as excessive (compared with the recommended dose of 3-15mg for treating parasitic infections) resulted in blood concentrations several orders of magnitude times lower than those needed to inhibit the virus.

Head louse on human hair
Great for killing head lice, but the jury’s still out on coronavirus. GillesSM/Wikimedia Commons, CC BY-SA

How much ivermectin is too much?

While ivermectin generally doesn’t cause problematic side effects at the currently used doses, there is limited information about whether much larger doses would also be safe.

Repurposing ivermectin as a “cure” for COVID-19 would require massive doses, which would substantially increase the risk of side effects such as nausea, rash, dizziness, immune suppression, abdominal pain, fever, raised heart rate and unstable blood pressure.

Ivermectin at usual doses does not enter the central nervous system, but after large doses of the drug it may enter the brain, potentially causing impaired vision, hampering the central nervous system (which could in turn affect breathing, heart rate and consciousness), and exaggerating the effects of other sedative medicines such as benzodiazepines.


Read more: Tested positive for COVID-19? Here's what happens next – and why day 5 is crucial


Ivermectin is a hugely useful medicine in treating parasitic illnesses such as lice, worms and scabies, particularly in developing countries. But as we have already seen in the case of the malaria drug hydroxychloroquine, just because a medicine is useful for one purpose, it cannot automatically be considered a miracle cure for COVID-19.

Repurposing drugs as COVID-19 treatments

Repurposing existing drugs as possible COVID-19 treatments is a smart strategy, but requires several key principles to be addressed. The drug must have antiviral effects in cells and animals at doses relevant to humans. The drug must be able to get to the site of infection in the body (or reduce the inflammation associated with the infection). It is best if the antiviral mechanism is understood. And finally, well designed clinical trials are needed to be sure the drugs works in people with the infection and it is safe to use (especially in older, vulnerable unwell people).

Thankfully, Australia’s National COVID-19 Clinical Evidence Taskforce continually assesses and updates the best evidence-based advice for treating COVID-19, which you can read here.

This article first appeared in The Conversation. It was republished with permission.

Times Magazine

With Nvidia’s second-best AI chips headed for China, the US shifts priorities from security to trade

This week, US President Donald Trump approved previously banned exports[1] of Nvidia’s powerful ...

Navman MiVue™ True 4K PRO Surround honest review

If you drive a car, you should have a dashcam. Need convincing? All I ask that you do is search fo...

Australia’s supercomputers are falling behind – and it’s hurting our ability to adapt to climate change

As Earth continues to warm, Australia faces some important decisions. For example, where shou...

Australia’s electric vehicle surge — EVs and hybrids hit record levels

Australians are increasingly embracing electric and hybrid cars, with 2025 shaping up as the str...

Tim Ayres on the AI rollout’s looming ‘bumps and glitches’

The federal government released its National AI Strategy[1] this week, confirming it has dropped...

Seven in Ten Australian Workers Say Employers Are Failing to Prepare Them for AI Future

As artificial intelligence (AI) accelerates across industries, a growing number of Australian work...

The Times Features

Why Fitstop Is the Gym Australians Are Turning to This Christmas

And How ‘Training with Purpose’ Is Replacing the Festive Fitness Guilt Cycle As the festive season ...

Statement from Mayor of Randwick Dylan Parker on Bondi Beach Terror Attack

Our community is heartbroken by the heinous terrorist attack at neighbouring Bondi Beach last nigh...

Coping With Loneliness, Disconnect and Conflict Over the Christmas and Holiday Season

For many people, Christmas is a time of joy and family get-togethers, but for others, it’s a tim...

Surviving “the wet”: how local tourism and accommodation businesses can sustain cash flow in the off-season

Across northern Australia and many coastal regions, “the wet” is not just a weather pattern — it...

“Go west!” Is housing affordable for a single-income family — and where should they look?

For decades, “Go west!” has been shorthand advice for Australians priced out of Sydney and Melbo...

Housing in Canberra: is affordable housing now just a dream?

Canberra was once seen as an outlier in Australia’s housing story — a planned city with steady e...

What effect do residential short-term rentals have on lifestyle and the housing market in Brisbane?

Walk through inner-Brisbane suburbs like Fortitude Valley, New Farm, West End or Teneriffe and i...

The Sydney Harbour Bridge faces tolls once again — despite tolls being abolished years ago. Why?

For many Sydney motorists, the Harbour Bridge toll was meant to be history. The toll booths cam...

The Victorian Paradox: how Labor keeps winning elections even when it feels “unpopular”

If you spend any time in a Melbourne café, a tradie ute yard, a Facebook comments section, or th...